Finnish pharmaceutical firm Orion has received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide plus androgen deprivation therapy (ADT) along with docetaxel to treat metastatic prostate cancer.

The oral androgen receptor inhibitor (ARi) darolutamide has a distinct chemical structure that attaches to the receptor with high affinity and shows strong antagonistic activity and inhibits the receptor function as well as prostate cancer cells growth.

Previously, the inhibitor, under the brand name Nubeqa, received approval to treat non-metastatic castration-resistant prostate cancer (nmCRPC) patients in the country.

The regulatory approval is based on the data obtained from the multi-centre, double-blind, placebo-controlled, randomised Phase III ARASENS clinical trial.

The trial assessed the safety and efficacy of oral darolutamide plus ADT and chemotherapy docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients.

In the trial, the combination therapy significantly reduced death risk by 32.5% compared to ADT with docetaxel in the indicated patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also demonstrated consistent benefits across clinically relevant secondary endpoints of the trial.

Recently, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) recommended darolutamide plus ADT and docetaxel for EU marketing authorisation to treat mHSPC.

The final regulatory decision is expected in the coming months.

Orion stated that darolutamide is being assessed in a wide development programme and has three additional ongoing or planned large trials.

These trials are designed to assess darolutamide’s potential across patients with prostate cancer from the early- to the late stage of this disease.

This includes the Phase III ARANOTE trial of darolutamide plus ADT against ADT alone for the treatment of mHSPC.